Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial
Journal of the American Academy of Dermatology Feb 09, 2018
Wally V, et al. - This trial aimed to compare the effect of 1% diacerein cream with the placebo for decreasing the number of blisters in epidermolysis bullosa simplex (EBS). Data exhibited that the changes in absolute blister numbers were marked for the diacerein group only. Hence, evidence was yielded regarding the impact of 1% diacerein cream for treating the EBS.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
